Skip to main content

Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022.

Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Therapy, will be participating in a fireside chat on Wednesday, November 30, 2022, beginning at 3:05pm Eastern Time. Athenex management will also be available for one-on-one investor meetings during the event. Please contact your representative at Evercore ISI to schedule a virtual one-on-one meeting with management during the conference.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments. For more information, please visit

Athenex Contacts

Daniel Lang, M.D.
Athenex, Inc.

Tim McCarthy
LifeSci Advisors, LLC

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.